TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06349265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Hydrodissection with %5 dextrose in water injection
Description: Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Hydrodissection with %5 dextrose in water injection
Description: Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Hydrodissection with %5 dextrose in water injection
Description: Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.
Study: NCT05396339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAE0972
Description: IAE0972 is an investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAE0972
Description: IAE0972 is an investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAE0972
Description: IAE0972 is an investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAE0972
Description: IAE0972 is an investigational product
Study: NCT05720052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553 oral tablet BID x 28-days
Study: NCT06291493

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fingerstick blood draw
Description: Capillary blood specimen collected from two separate fingerstick blood draws.
Study: NCT06395896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Cancer Prevention Journey Program Group
Description: The researcher will invite individuals to the study at Necip Fazıl Family Center and conduct a pre-test application. The day and time for the Fight Against Breast Cancer training, which is structured based on the Health Belief Model prepared by the researchers, will be determined and announced to the participants. The training will be held in a single session of 45-60 minutes. Slide presentation and a breast model showing the symptoms of breast cancer will be used as training materials. At the end of the training, it will be announced that free shuttle service will be provided for mammography screening and individuals will be invited to screening. On the specified day and time, participants will be taken to the Cancer Early Diagnosis, Screening and Education Center (KETEM) in Mamak and mammography screening will be performed. After the screening, a post-test will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Cancer Screening Program Group
Description: Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Health Ministry of Türkiye offers free mammography screening for breast cancer to women over the age of 40. In this context, women are called to the centers by phone and mammography screening is performed free of charge.
Study: NCT03932318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lintuzumab-Ac225
Description: In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
Study: NCT04646837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle
Study: NCT05223569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home OCT monitoring model
Description: A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-based monitoring with a staff-administrated OCT
Description: Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
Study: NCT05619094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corrective exercise program
Description: Strengthening exercises for deep cervical flexor muscles and shoulder retractors.~Stretching exercises for cervical extensors and pectoral muscles.
Study: NCT04646837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/Cisplatin
Description: Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle
Study: NCT06398093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Tool Kit
Description: Participants will mediate, journal their reactions, exercise, and apply sleep hygiene measures over the course of four weeks.
Study: NCT06136455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine Clinical Solutions Teeth Strength
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
Study: NCT04996160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg/m2/day divided BID, PO, NG, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg/m2/day divided BID, PO, NG, or IV
Study: NCT02388477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: antibiotic used to treat infection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: placebo with no pharmacologic effect
Study: NCT04870463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary and mandibular Cone Beam Computed Tomography record
Description: A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary and mandibular Cone Beam Computed Tomography record
Description: A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
Study: NCT05521191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS8429
Description: Solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS8429
Description: Solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for subcutaneous injection
Study: NCT05466136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental fatigue condition
Description: In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
Study: NCT04637776

Intervention type: OTHER
Intervention: Hospitalization
Description: Hospitalization for any reason
Study: NCT04662190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printing model/guide.
Description: Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgery
Description: Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
Study: NCT05561439

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
Study: NCT06136455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine Total Care Zero Alcohol Mouthwash
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint Zero Alcohol Mouthwash
Description: After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.

Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
Study: NCT06263205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Dressing of Surgical Wound
Description: In this intervention, participants undergoing gastrointestinal tumor surgery will receive standard wound disinfection and initial postoperative care, which includes the application of dressings immediately after surgery. However, unlike traditional methods, the dressings will be removed 48 hours post-surgery, and the surgical wounds will then be left exposed without any further dressing. This method is intended to evaluate the effects of an exposed surgical wound on healing, pain, and healthcare costs, compared to traditional dressing methods.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Dressing Change of Surgical Wound
Description: This intervention involves the standard postoperative wound care for participants with gastrointestinal tumors. After surgery, the surgical wounds will be disinfected and covered with dressings. These dressings will be changed every 48-72 hours, following traditional wound management practices. The purpose of this intervention is to serve as a comparator for assessing the effectiveness of the non-dressing approach, focusing on wound healing, pain management, and healthcare costs.
Study: NCT04985864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulation
Description: tDCS brain stimulation on leg motor areas was applied to stroke patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill gait training
Description: Lokomat robot training was applied to stroke patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Description: Lokomat robot training was applied to stroke patients.
Study: NCT06440096

Intervention type: DIAGNOSTIC_TEST
Intervention: hemogram
Description: hemogram

Intervention type: DIAGNOSTIC_TEST
Intervention: hemogram
Description: hemogram
Study: NCT04996160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2/dose, IV (preferred) or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2/dose, IV (preferred) or SC
Study: NCT05392049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen's therapy
Description: Bowens technique will be apply on patients of TMJ for 2 repetitions in 1 set, 4 sets in each session for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation
Description: post isometric relaxation technique and jaw exercises (strengthen the weakened muscles, stretch the shortened muscles) with dosage 5 times/session, 5 sec rest and 2times/week for 4 weeks will apply on patients.
Study: NCT05793684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period A
Description: Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period A
Description: Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period A
Description: Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period A
Description: Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period A
Description: Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period A
Description: Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period B
Description: Week 1: AD816 low dose; Week 2: AD816 high dose
Study: NCT05561439

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
Study: NCT05793684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period B
Description: Week 1: AD816 low dose; Week 2: AD816 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period B
Description: Week 1: AD816 low dose; Week 2: AD816 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period B
Description: Week 1: AD816 low dose; Week 2: AD816 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period B
Description: Week 1: AD816 low dose; Week 2: AD816 high dose
Study: NCT05561439

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021

Intervention type: OTHER
Intervention: Dosimetric monitoring
Description: Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
Study: NCT04922372

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: peek
Description: After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: peek
Description: After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
Study: NCT05372978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: Participants will receive a one-time unconditional cash transfer of $8,500.
Study: NCT05745337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
Description: Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
Study: NCT05123339

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire
Study: NCT06099223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6.
Study: NCT04162639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skin allograft
Description: Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skin allograft
Description: Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skin allograft
Description: Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
Study: NCT06096753

Intervention type: DEVICE
Intervention: Bruxoff gnathological function analysis
Description: The recordings will be carried out for 3 randomly selected nights within 3 weeks, with at least 4 hours of sleep per night.

Intervention type: DEVICE
Intervention: Bruxoff gnathological function analysis
Description: The recordings will be carried out for 3 randomly selected nights within 3 weeks, with at least 4 hours of sleep per night.
Study: NCT05346874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teysuno
Description: Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Description: In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
Study: NCT04996160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2/dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2/dose IV